Newswise Feature Channel: Biotech2d agoInhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC StudyInhibrx Biosciences, Inc.Read at Newswise Feature Channel: BiotechShareLess like this
